Zhejiang Tianyuan Bio-Pharmaceutical, Hangzhou-based vaccine producer, has been conducting clinical trial use of H1N1 flu vaccine designed for children between 6 to 35 months old.

Zhejiang Tianyuan Bio-Pharmaceutical

The clinical trials began at the beginning of last December and were conducted in three bases in provincial-level areas including Guangxi, Jiangsu and Hunan, according to the Ministry of Health.

Together with Zhejiang Tianyuan Bio-Pharmaceutical, Beijing-based Sinovac Biotech Company and Shanghai Institute of Biological Products were responsible for conducting the tests.

"As of December 25, none of the volunteers has exhibited any signs of severe adverse reactions after receiving the first shot," the Ministry of Health said.

Among 935 participants, 209 were children between 6 to 12 months old, 363 aged one, and 363 aged two.

The ministry and the State Food and Drug Administration approved the trials to better protect children aged below three, who have a high risk to infect the H1N1 strain.

Zhejiang Tianyuan Bio-Pharmaceutical is a fast-growing developer, producer, and distributor of bio-pharmaceutical products in China. Since 1989 the company successfully established its national and international vaccine business with the intention to provide high quality vaccines of international standard, and contribute to the prevention of diseases in China and throughout the world.

By Xie Fang